1882 ewggd 2012. phenotype spectrum of hematological and visceral disease in type 3 gaucher disease...

1882

EWGGD 2012

Phenotype Spectrum of Hematological and Visceral Disease in Type 3 Gaucher Disease –

Genotype Correlations and Response to Imiglucerase Therapy in 325 Patients from the ICGG Registry

Phenotype Spectrum of Hematological and Visceral Disease in Type 3 Gaucher Disease –

Genotype Correlations and Response to Imiglucerase Therapy in 325 Patients from the ICGG Registry

Pramod MistryDepartment of Pediatrics and Medicine.

Yale University School of Medicine, New Haven, CT, USA

On behalf of :

Edwin H. Kolodny1, Anna Tylki-Szymanska2, Nadia Belmatoug3, Juan F. Cabello4, Ashok Vellodi5, J. Alexander Cole6, Amal El-Beshlawy7, Gregory Grabowski8

1New York University School of Medicine, New York, USA; 2Children’s Memorial Health Institute, Warsaw, Poland; 3Centre de Référence des Maladies Lysosomales Assistance Publique-Hôpitaux de Paris Service de Médecine Interne Hôpital, Beaujon, France; 4Laboratorio de Genetica y Enfermedades Metabolicas. INTA, Universidad,de Chile, Santiago, Chile; 5Great Ormond Street Childrens' Hospital NHS Trust, London, UK; 6Biostatistics/Epidemiology, Genzyme, a Sanofi company, Cambridge, MA, USA; 7Pediatric Hospital of Cairo University, Cairo, Egypt; 8Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA

Pramod MistryDepartment of Pediatrics and Medicine.

Yale University School of Medicine, New Haven, CT, USA

On behalf of :

Edwin H. Kolodny1, Anna Tylki-Szymanska2, Nadia Belmatoug3, Juan F. Cabello4, Ashok Vellodi5, J. Alexander Cole6, Amal El-Beshlawy7, Gregory Grabowski8

1New York University School of Medicine, New York, USA; 2Children’s Memorial Health Institute, Warsaw, Poland; 3Centre de Référence des Maladies Lysosomales Assistance Publique-Hôpitaux de Paris Service de Médecine Interne Hôpital, Beaujon, France; 4Laboratorio de Genetica y Enfermedades Metabolicas. INTA, Universidad,de Chile, Santiago, Chile; 5Great Ormond Street Childrens' Hospital NHS Trust, London, UK; 6Biostatistics/Epidemiology, Genzyme, a Sanofi company, Cambridge, MA, USA; 7Pediatric Hospital of Cairo University, Cairo, Egypt; 8Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA

Background

In Gaucher disease, the phenotype spectrum and response to imiglucerase therapy have been characterized in detail for the non-neuronopathic Type 1 Gaucher disease in many large studies.

Fewer analyses have focused on long-term outcomes in Type 3 Gaucher disease.

Type 3 Gaucher disease

Onset Before 2 years or later Types 3a, 3b and 3c

Typical neurological manifestations Oculomotor apraxia Supranuclear ophthalmoplegia Extrapyramidal features Myoclonic or generalized seizures Cerebellar ataxia Developmental delay

152,

860K

152,

870K

152,

880K

152,

890K

152,

900K

152,

910K

152,

920K

152,

930K

152,

940K

152,

950K

CL

K2

SC

AM

P3

C1o

rf2

GB

Aps

MT

X1

TH

BS

3

psG

BA

MT

X1

Ch

r. 1

1q

211

q22

152,

860K

152,

870K

152,

880K

152,

890K

152,

900K

152,

910K

152,

920K

152,

930K

152,

940K

152,

950K

CL

K2

SC

AM

P3

C1o

rf2

GB

Aps

MT

X1

TH

BS

3

psG

BA

MT

X1

Ch

r. 1

1q

211

q22

*

*

Neuronopathic L444P GBA Mutation – Likely the most common disease mutation

world-wide

International Collaborative Gaucher Group (ICGG)Gaucher Registry

An observational database of phenotype, genotype and treatment status of patients with Gaucher disease

Supported by Genzyme Sanofi, governed by international physician experts in Gaucher disease.

The largest database of GD with >6,000 GD patients from 60 countries.

Objectives and Analysis Plan

What are the correlates of baseline hematological, growth, and visceral organ status in GD3?

Set of multivariate regressions to characterize baseline status as a function of covariates

What are the predictors of hematological, growth, and visceral organ outcomes in GD3?

Second set of multivariate regressions to characterize outcomes as a function of covariates

Methods: Study Population

Study Population All patients <18 years of age at the start of therapy

Enrolled in the ICGG Gaucher Registry as of July 2010

Diagnosis of type 3 Gaucher disease

Subsets of patients with baseline data Anemia Thrombocytopenia Splenomegaly Hepatomegaly Height z-score ≤-1

Statistical Analysis

Statistical Analysis Non-linear mixed effects models

Alpha-level of 0.05 for statistical significance

SAS 9.1 (SAS Institute, Cary, NC)

Results

Patient Characteristics (N=344)

Male 166 (49.7) Female 168 (50.3)

0‡ to <6y 291 (89.8) 6 to <12y 24 (7.4) 12 to <18y 9 (2.8)

65.8 (58.26)

0 to <6y 270 (80.8) 6 to <12y 44 (13.2) 12 to <18y 20 (6.0)

Age at First Infusion, n(%)

Gender, n(%)

Age at Diagnosis, n(%)

Treatment dose, mean±SD, U/kg per 2 wk

‡Diagnosed prenatally.

Patient Characteristics

Latin America 30 (9.0) Europe 98 (29.3) Middle East 114 (34.1) Asia, Pacific 30 (9.0) USA 54 (16.2) Canada 8 (2.4)Genotype, n(%) n=260 L444P/L444P 164 (63.1) L444P/OTHER 41 (15.8) OTHER/OTHER 55 (21.1)

Geographic Distribution, n(%)

*13 patients are D409H/D409H

70% of disease alleles are L444P and 2.5% D409H

Effects of ERT

At Diagnosis

L444P Homozygous GD3

After 4 years of imiglucerase

Courtesy of Dr Amal El-Beshlawy, University of Cairo

Age at first infusion (n=366)

Scatter plot of age at first infusion x baseline hemoglobin (g/dl) (n=283)

Scatter plot of age at first infusion x baseline platelet count (x103/mm3) (n=287)

Baseline Hemoglobin: Linear Regression, n=247

Estimate (Standard error) p-value

Intercept 9.74( 0.52) <.0001

Covariates

Ever splenectomized 0.10( 0.38) 0.802

Age categories at first infusion

>0 - < 2 referent referent

>2 - < 10 0.25( 0.38) 0.5056

>10 - < 18 1.45( 0.58) 0.0136

Age categories at diagnosis


>2 0.02( 0.37) 0.9604

Genotype categories

L444P/L444P referent referent

L444P/OTHER 0.52( 0.38) 0.1741

OTHER/OTHER 0.68( 0.35) 0.0548

Baseline Platelet Count: Linear Regression (non-splenectomized patients), n=213


Intercept 151.4(33.55) <.0001

Covariates



>2 - < 10 -39.3(21.75) 0.0725

>10 - < 18 -40.5(36.88) 0.2739



>2 -13.5(22.51) 0.5492

Genotype categories


L444P/OTHER 15.14(21.85) 0.4894

OTHER/OTHER 24.95(19.71) 0.2076

Baseline Liver Volume (MN): Linear Regression, n=101


Intercept 2.95( 0.40) <.0001

Covariates

Ever splenectomized -0.13( 0.29) 0.6689



>2 - < 10 -0.07( 0.26) 0.8048

>10 - < 18 -0.48( 0.48) 0.3217



>2 -0.14( 0.25) 0.577

Genotype categories


L444P/OTHER -0.09( 0.31) 0.7684

OTHER/OTHER -0.61( 0.28) 0.0339

Baseline Spleen Volume (MN): Linear Regression (non-splenectomized patients), n=101


Intercept 69.81( 7.42) <.0001

Covariates



>2 - < 10 -1.84( 4.36) 0.6743

>10 - < 18 -3.77(10.51) 0.7213



>2 -0.62( 4.33) 0.887

Genotype categories


L444P/OTHER -14.1( 5.05) 0.0068

OTHER/OTHER -14.4( 4.51) 0.0022

Baseline Height Z-Score: Linear Regression, n=215


Intercept -1.39( 0.48) 0.0045

Covariates

Ever splenectomized -0.56( 0.34) 0.1023



>2 - < 10 -0.76( 0.36) 0.0363

>10 - < 18 -1.27( 0.57) 0.0266



>2 0.23( 0.35) 0.5209

Genotype categories


L444P/OTHER 0.83( 0.38) 0.0285

OTHER/OTHER 0.79( 0.32) 0.0155

Hemoglobin During Follow-Up

N 235 209 180 159 141 130Median 9.40 10.40 11.40 11.60 11.80 11.90Mean 9.40 10.35 11.33 11.44 11.66 11.75

Years Following Initiation of Therapy

0 1 2 3 4 50.00

5.00

10.00

15.00

20.00H

emo

glo

bin

(g

/dL

)

Platelet Count During Follow-Up

N 203 181 154 133 115 107Median 101.0 137.0 195.0 208.0 212.0 203.0Mean 128.3 159.4 228.8 228.1 218.1 210.6


0 1 2 3 4 5

0.00

200.00

400.00

600.00

800.00

1000.00P

late

let

Co

un

t (X

103

/mm

3)

Liver Volume During Follow-Up

N 85 69 63 54 42 36Median 2.19 1.72 1.54 1.39 1.28 1.18Mean 2.35 1.86 1.57 1.43 1.32 1.26


0 1 2 3 4 5

0

2

4

6

8L

ive

r V

olu

me

in M

ult

iple

s o

f N

orm

al

Spleen Volume During Follow-Up Among Non-Splenectomized Patients

N 87 70 65 55 45 42Median 37.49 31.60 24.01 20.73 16.78 14.33Mean 38.17 29.16 24.46 19.04 16.06 14.46


0 1 2 3 4 5

0

25

50

75

100S

ple

en V

olu

me

in M

ult

iple

s o

f N

orm

al

Height Z-Score During Follow-Up

N 197 174 148 135 120 114Median -2.04 -2.40 -2.02 -1.63 -1.60 -1.45Mean -2.22 -2.26 -2.01 -1.63 -1.50 -1.41


0 1 2 3 4 5-10.0

-7.5

-5.0

-2.5

0

2.5H

eig

ht

Z-S

core

Cause of Death

54 out of 325 (17%) patients died and had reported causes of death.

The most frequently cited causes of death were: Progressive neurological disease

Infections

Cardiac complications

Malignancy

Kaplan-Meier Analysis


0 5 10 15 20

Patients at Risk n = 325 n = 195 n = 90 n = 35 n = 0

0

20

40

60

80

100P

rop

ort

ion

of

Pat

ien

ts A

live Survival

Lower 95% CL

Upper 95% CL

Number of Patients:

Number of Deaths:

325:

54 (17%)

Conclusions

There is early onset of prominent visceral and hematologic disease in patients with GD3 before the age of 6 years. Moreover, these patients exhibit striking growth failure.

These effects are rapidly reversed by alglucerase/ imiglucerase treatment, with improvement within 5 years of treatment.

This cohort represents the largest cohort of children with type 3 Gaucher disease ever described to delineate the phenotypic spectrum and its response to alglucerase/ imiglucerase therapy.

1882 ewggd 2012. phenotype spectrum of hematological and visceral disease in type 3 gaucher disease...

Documents

usa slide

gaucher disease onset

visceral disease

new haven

genzyme sanofi

sanofi company

gd patients

baseline status